California
Association
for
Medical Laboratory Technology
Distance Learning Program
|
Hematology
Case Studies: Platelets
Course
Number: DL-985 © California Association
for Medical Laboratory Technology. CAMLT is approved by the California Department
of Health Services as a 1895 Mowry Ave, Suite 112 Notification of Distance Learning Deadline |
| This course is configured to be completed on-line. You can register
for the course, submit secure payment using a credit card via PayPal,
take the quiz on-line and receive your graded score.
If you pass, your certificate will be mailed to you from
the CAMLT office. If you fail, you must submit new payment and obtain a new PayPal receipt each time you take the test. A certificate will be issued only if you have paid for re-taking the course and you pass the test. If you want to submit your registration and quiz via fax or mail you should print the Adobe Acrobat version of the course which includes the required Registration/Quiz form. |
| Links to: On-line REGISTRATION, PAYMENT and QUIZ Printable Acrobat version of this course * Review Questions at the end of this Course Other Distance Learning Courses |
|
HEMATOLOGY CASE STUDIES: PLATELETS
ATTENTION Photos for this course are included ONLY in the
.pdf download. |
OBJECTIVES:
After completing this course the participant will be able to:
1. Differentiate among the causes of thrombocythemia.
2. Explain how to determine the platelet count when the count is above the upper
reportable range of the analyzer.
3. Estimate the platelet count from the blood smear.
4. List the signs and symptoms of Essential Thrombocythemia.
5. Enumerate the causes of thrombocytopenia.
6. Discuss the causes of pseudothrombocytopenia.
7. Explain the methods of determining the causes of pseudothrombocytopenia.
Case #1
A 44-year-old woman comes in for a complete blood count (CBC) as part of a routine
physical exam. The results from the hematology analyzer, Cell-Dyn 1700 (Abbott
Diagnostics), are:
| WBC | 7.5 K/µL | RBC | 4.22 M/µL |
| Lym | 28.7 % | HGB | 12.4 g/dL |
| MID* | 10.4 % | HCT | 38.6 % |
| Gran | 60.9 % | MCV | 91.4 fL |
| MCH | 29.3 pg | ||
| PLT | >>>> K/µL | MCHC | 32.0 g/dL |
| RDW | 13.5 % | ||
| *MID cells may include less frequently occurring and rare cells correlating to monocytes, eosinophils, basophils, blasts, and other precursor white cells. | |||
Questions:
1. What is abnormal about her CBC?
2. Which parts can be reported?
3. What procedures can be done regarding the abnormal result?
Answers:
1. The platelet count is above the upper reportable range.
2. The WBC histogram and 3-part differential are normal and can be reported.
The RBC histogram is normal and can be reported.
3. To determine the platelet count:
a. Make a 1:1 dilution of the whole blood and re-run the
platelet count. Correct the platelet count for the dilution.
b. Make a smear of the whole blood and examine for platelet
morphology and numbers.
Discussion:
The platelet count on 1:1 diluted blood was 534, so the
platelet count is 2 x 534 = 1,068 K/µL (normal is 150-400 K/µL).
On blood smears made from EDTA-blood and stained with a
Romanowsky stain, platelets are round or oval, 2-4 µm in diameter, and
separated from one another. The platelet count can be estimated from the smear.
At 1000x magnification (oil immersion), this is equivalent to about 7-30 platelets
per oil immersion field (OIF). Count the number of platelets in 10 oil immersion
fields. Divide the total by 10 to get the average number of platelets per field.
Each platelet seen on the smear equates to approximately 15,000/µL. Multiply
the average number per OIF to get the platelet estimate (1). See Image #1. In
this case the average number of platelets per field was 70. The estimate equals
70 x 15,000 = 1,050 K/µL. Thus the platelet estimate derived from the
smear in Images #1 and #2 correlates with the corrected platelet count of 1,068
K/µL.
Images 1 and 2 (download .pdf file above
to view these images)
| The causes of increased platelet counts include: | |
|
|
Since the patient had no symptoms, no history of splenectomy,
and normal WBC and RBC hemograms, all except essential (primary) thrombocythemia
can be eliminated or are unlikely.
Essential (Primary) Thrombocythemia (2)
Essential thrombocythemia (ET) is a myeloproliferative disease.
These diseases are a group of disorders that share features that include the
clonal overproduction of one or more blood cell lines. Clonal diseases begin
with a mutation in one or more bone marrow cell lines. Myeloproliferative diseases
include polycythemia vera, myelofibrosis, chronic granulocytic leukemia, and
essential thrombocythemia.
In ET there is overproduction of megakaryocytes, the precursor to platelets
(thrombocytes). Abnormalities in platelet aggregation and adhesiveness tests
suggest defective platelet function (3). In about half the patients with ET
there is a mutation of the JAK2 (Janus kinase 2) gene in their blood cells.
In the others the cause is unknown.
ET occurs mostly in adults. There are about 0.1 to 2.4 new
cases per 100,000 in the U.S. each year. The disease does not ordinarily shorten
life expectancy, but serious complications can occur, so the patient needs to
be followed by a physician.
Many patients have no symptoms. In others signs, symptoms
and complications of ET result from the increased numbers of platelets in the
peripheral blood. Since platelets are involved in the process of clot formation
in response to blood vessel injury, the most common complication of ET is blockage
of blood vessels by excess platelets (thrombosis). Less often the increased
platelets cause bleeding.
Signs, symptoms, and complications include:
| WBC | 8.9 K/µL | RBC | 4.86 M/µL |
| NE | 57.9 % | HGB | 14.4 g/dL |
| LY | 33.4 % | HCT | 42.5 % |
| MO | 6.3 % | MCV | 87.4 fL |
| EO | 1.9 % | MCH | 29.8 pg |
| BA | 0.5 % | MCHC | 34.0 g/dL |
| RDW | 12.5 % | ||
| PLT | 64 K/fL | ||
| MPV | 6.9 fL | ||
| Suspect/Definitive Messages/Flags: Micro/Fragmented Red Cells Giant Platelets Platelet clumps |
R flag on Platelet Count & MPV Comments: Do not verify platelets; review first and redraw if necessary |
||
Image 3 (download .pdf file above to view
this image)
Discussion:
The platelet count was below normal, a condition known as thrombocytopenia.
The causes of decreased platelet counts are (4):
Results of the blood smear evaluation (Case #2, Image #3):
The smear showed numerous platelet clumps (make sure to
examine the edges of the smear since the clumps may migrate there; Images #4
and #5). There were no giant platelets, fragmented RBC, or small RBC. To obtain
an automated platelet count, obtain a blood specimen drawn into Sodium Citrate
(NaCitrate).
Images 4 and 5 (download .pdf file above
to view these images)
Results of the platelet count on the NaCitrate specimen (Case #2, Image #6):
There were no flags or error messages. The platelet count
of 289 K/µL needs to be corrected for the dilution of the blood by liquid
NaCitrate as follows:
289 x 1.1 (dilution factor) = 318 K/µL
The diagnosis is EDTA-platelet clumping. This condition may persist for decades
without any evidence of abnormal hemostasis. EDTA-platelet clumping needs to
be recognized and documented in the patient’s chart to prevent unnecessary
treatment for thrombocytopenia, and to guide future laboratory tests.
Image 6 (download .pdf file above to view
this image)
Causes of pseudothrombocytopenia are as follows:
Partial clotting of the specimen:
With a low platelet count the first procedure is to examine the specimen for evidence of clotting as well as to make a smear and look for evidence of platelet clumping. When blood clots, platelets adhere to the clot and are removed from the fluid blood. If evidence of micro-clots or clumping is seen, obtain a new specimen.
EDTA-Induced Platelet Agglutination (EIPA) (EDTA-platelet clumping):
EIPA is an in-vitro phenomenon due to the presence of naturally occurring autoantibody against a cryptantigen on the GPIIb/IIIa platelet receptor. Under normal in vivo conditions this antigen is not accessible for antibody binding (crypt or hidden antigen). When calcium is chelated by EDTA, the GPIIb protein undergoes a structural change that exposes the cryptantigen. The antibody can then bind to the exposed site and crosslink to other platelets causing agglutination. The condition occurs in 0.1 to 2% of hospitalized patients (5).
Platelet satellitism
In this phenomenon platelets rosette around neutrophils or rarely around other cells. The satellite platelets are not counted by automated cell counters, resulting in spurious thrombocytopenia. Platelet satellitism is caused by EDTA-dependent antiplatelet and antineutrophil IgG antibodies in the patient’s plasma (5).
The phenomenon has not been associated with any disease state or drug and is thought to be benign.
The diagnosis is made by making a blood smear and looking for platelet rosettes: Images #7 and #8. This needs to be documented in the patient’s chart.Images 7 and 8 (download .pdf file above to view these images)
Cold agglutinins
Spontaneous EDTA-independent agglutination associated with cold antibodies is rare. The condition should be considered when agglutination occurs in citrate and heparin as well as EDTA anticoagulants. This phenomenon is temperature dependent. The specimen should be maintained at 37∞ C or warmed to 37∞ C to obtain an accurate platelet count (6).
Giant platelets
Giant platelets that are 36 fL or larger will be counted as red cells (See Images #9 and #10) in most automated electronic platelet counters, resulting in spuriously low platelet counts. Low platelet counts along with instrument flagging of giant platelets should prompt the operator to confirm the abnormal platelet count by blood smear review/platelet estimate or perform a manual platelet count. The confirmatory method of choice employs a manual platelet count using phase-contrast microscopy. Manual platelet counts include three steps: dilution of the blood with simultaneous lysis of RBCs with ammonium oxalate; sampling the diluted suspension into a measured volume using a hemocytometer; and counting the platelets in that volume (1). When significant numbers of giant platelets are counted as red cells, spuriously low platelet counts cannot be reported. The platelet estimate or manual platelet count must be reported in the place of automated platelet count.
Images 9 and 10 (download .pdf file above
to view these images)
ACKNOWLEDGMENTS
Major funding for photographs used in this presentation was provided by:
All images were photographed by Dora W. Goto, MS, CLS, MT(ASCP). Many thanks also to the laboratory staff at Bay Valley Medical Group, Hayward, CA for saving instrument printouts and corresponding blood smears in support of continuing medical technology education.
REFERENCES: